Alto Neuroscience, Inc. (ANRO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Company: Alto Neuroscience, Inc.
Reporting Period: Quarter and six months ended June 30, 2025
Business Model: Clinical-stage biopharmaceutical company focused on developing personalized treatments for psychiatric disorders (MDD, BPD, TRD, schizophrenia) using a Precision Psychiatry Platform.
Status: Emerging Growth Company and Smaller Reporting Company. No product revenue generated to date.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(17,706) | $(16,030) | $(32,875) | $(29,447) |
| Loss Per Share (Basic/Diluted) | $(0.65) | $(0.60) | $(1.21) | $(1.32) |
| Operating Expenses | $18,682 | $18,341 | $34,358 | $32,727 |
| Cash & Equivalents (End of Period) | $147,585 | $168,229 | $147,585 | $168,229 |
| Net Cash Used in Operating Activities (YTD) | $(30,335) | $(22,677) | $(30,335) | $(22,677) |
| Total Debt (Principal) | $20,000 | $10,000 | $20,000 | $10,000 |
Note: Debt figures represent principal balance of the Amended Term Loan. Convertible Grant Agreement liability is recorded at fair value ($2.0 million).
Material Changes vs. Prior Period
- Debt Restructuring: In January 2025, the Company amended its loan agreement with K2 HealthVentures, increasing the facility to $75 million and drawing an additional $20 million (total outstanding principal $20 million). This resulted in a $0.7 million loss on debt extinguishment recorded in the first half of 2025.
- Asset Acquisition: In May 2025, the Company acquired ALTO-207 and ALTO-208 from Chase Therapeutics for an initial payment of $1.8 million plus $1.2 million in expense reimbursements, with up to $71.5 million in potential future milestones.
- Operating Expenses: R&D expenses remained relatively flat YTD ($23.1 million in 2025 vs. $23.1 million in 2024), driven by decreased costs for ALTO-100 and ALTO-300 trials offset by acquisition fees and increased personnel costs. G&A expenses increased by $1.7 million YTD due to higher professional fees and personnel costs.
- Interest Income: Decreased significantly due to lower interest rates on cash equivalents ($3.5 million YTD 2025 vs. $4.2 million YTD 2024).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash ($147.6 million) plus anticipated proceeds from the Wellcome Trust Convertible Grant Agreement will fund operations into 2028.
- Clinical Milestones:
- ALTO-100: Phase 2b trial in Bipolar Depression ongoing; topline data expected H2 2026.
- ALTO-300: Phase 2b trial in MDD ongoing; favorable interim analysis in Feb 2025; topline data expected mid-2026.
- ALTO-101: Phase 2 POC trial in Schizophrenia ongoing; topline data expected H2 2025.
- ALTO-207: Phase 2b trial initiation expected mid-2026.
- Stock Option Repricing: In July 2025, the Board approved repricing outstanding options to $2.35/share, expected to result in an incremental $1.5 million in stock-based compensation expense.
- Legal Proceedings: A putative securities class action lawsuit was filed on July 21, 2025, alleging violations related to the February 2024 IPO and disclosures regarding ALTO-100. The Company intends to dismiss the claims.
- Risk Factors: Continued operating losses, dependence on successful clinical trials, need for additional capital, and potential dilution from debt conversion features or equity raises.
Investor Verification Checklist
- Cash Runway: Verify the $147.6 million cash balance against the projected burn rate to confirm the "into 2028" liquidity estimate.
- Debt Covenants: Review the Amended Loan Agreement covenants, specifically the requirement to maintain a 5-month cash runway starting Jan 1, 2026 (waived if market cap > $700M).
- Convertible Grant Agreement: Assess the likelihood of achieving milestones to draw the remaining ~$9.7 million from the Wellcome Trust facility.
- Legal Exposure: Monitor the status of the July 2025 securities class action lawsuit and potential settlement costs.
- Stock-Based Compensation: Track the impact of the July 2025 option repricing on future quarterly expenses.